Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ruxolitinib · 1 trial · 1 indication
The percent of patients with response will be assessed at the protocol specified timepoints according to the Revised IWG-MRT and ELN Response Criteria for MF (2013)
| Arm | Type | Description |
|---|---|---|
| 9-ING-41 | EXPERIMENTAL | 9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days. |
| 9-ING-41 plus Ruxolitinib | EXPERIMENTAL | 9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count. |
| Name | Type | Description |
|---|---|---|
| Ruxolitinib | DRUG | Ruxolitinib at protocol-specified doses for given platelet count |
| 9-ING-41 | DRUG | 9- |
Inclusion Criteria: Patient - 1. Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures 2. Is aged ≥ 18 years 3. Has documented di...
Ruxolitinib is a small molecule being studied for the treatment of myelofibrosis, a type of bone marrow cancer. It is currently in Phase 2 clinical development and is being investigated by Actuate Therapeutics, Inc. The drug is intended for patients with this condition, and a clinical trial has been completed to evaluate its effects.
Ruxolitinib is being developed by Actuate Therapeutics, Inc., a biopharmaceutical company. The company's stock ticker is ACTU. Actuate Therapeutics is conducting clinical research on this drug for the treatment of myelofibrosis, and it is currently in Phase 2 development.
Ruxolitinib is in Phase 2 clinical development for the treatment of myelofibrosis. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its safety and efficacy in patients with this condition.
Ruxolitinib has been studied in a clinical trial with the identifier NCT04218071, titled 'Actuate 1901: 9-ING-41 in Myelofibrosis.' This Phase 2 trial was completed and enrolled 17 participants in the United States. The trial was controlled but not randomized or double-blinded, and it included adults aged 18 years and older.
Yes, Ruxolitinib is also known as 9-ING-41. The clinical trial NCT04218071, titled 'Actuate 1901: 9-ING-41 in Myelofibrosis,' refers to the drug by this alternative name. This information is relevant for readers who may encounter the drug under its alternative designation.